246 related articles for article (PubMed ID: 31113759)
1. Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease.
Vergallo A; Mégret L; Lista S; Cavedo E; Zetterberg H; Blennow K; Vanmechelen E; De Vos A; Habert MO; Potier MC; Dubois B; Neri C; Hampel H; ;
Alzheimers Dement; 2019 Jun; 15(6):764-775. PubMed ID: 31113759
[TBL] [Abstract][Full Text] [Related]
2. Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis.
De Meyer S; Schaeverbeke JM; Verberk IMW; Gille B; De Schaepdryver M; Luckett ES; Gabel S; Bruffaerts R; Mauroo K; Thijssen EH; Stoops E; Vanderstichele HM; Teunissen CE; Vandenberghe R; Poesen K
Alzheimers Res Ther; 2020 Dec; 12(1):162. PubMed ID: 33278904
[TBL] [Abstract][Full Text] [Related]
3. Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease.
Chatterjee P; Elmi M; Goozee K; Shah T; Sohrabi HR; Dias CB; Pedrini S; Shen K; Asih PR; Dave P; Taddei K; Vanderstichele H; Zetterberg H; Blennow K; Martins RN
J Alzheimers Dis; 2019; 71(3):775-783. PubMed ID: 31424403
[TBL] [Abstract][Full Text] [Related]
4. The Relationship Between Plasma Aβ Levels, Cognitive Function and Brain Volumetrics: Sydney Memory and Ageing Study.
Poljak A; Crawford JD; Smythe GA; Brodaty H; Slavin MJ; Kochan NA; Trollor JN; Wen W; Mather KA; Assareh AA; Ng PC; Sachdev PS
Curr Alzheimer Res; 2016; 13(3):243-55. PubMed ID: 26679856
[TBL] [Abstract][Full Text] [Related]
5. High performance plasma amyloid-β biomarkers for Alzheimer's disease.
Nakamura A; Kaneko N; Villemagne VL; Kato T; Doecke J; Doré V; Fowler C; Li QX; Martins R; Rowe C; Tomita T; Matsuzaki K; Ishii K; Ishii K; Arahata Y; Iwamoto S; Ito K; Tanaka K; Masters CL; Yanagisawa K
Nature; 2018 Feb; 554(7691):249-254. PubMed ID: 29420472
[TBL] [Abstract][Full Text] [Related]
6. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease.
Chatterjee P; Pedrini S; Stoops E; Goozee K; Villemagne VL; Asih PR; Verberk IMW; Dave P; Taddei K; Sohrabi HR; Zetterberg H; Blennow K; Teunissen CE; Vanderstichele HM; Martins RN
Transl Psychiatry; 2021 Jan; 11(1):27. PubMed ID: 33431793
[TBL] [Abstract][Full Text] [Related]
7. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
8. Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer's disease.
Lin SY; Lin KJ; Lin PC; Huang CC; Chang CC; Lee YC; Hsiao IT; Yen TC; Huang WS; Yang BH; Wang PN
Alzheimers Res Ther; 2019 Dec; 11(1):111. PubMed ID: 31881963
[TBL] [Abstract][Full Text] [Related]
9. Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70.
Keshavan A; Pannee J; Karikari TK; Rodriguez JL; Ashton NJ; Nicholas JM; Cash DM; Coath W; Lane CA; Parker TD; Lu K; Buchanan SM; Keuss SE; James SN; Murray-Smith H; Wong A; Barnes A; Dickson JC; Heslegrave A; Portelius E; Richards M; Fox NC; Zetterberg H; Blennow K; Schott JM
Brain; 2021 Mar; 144(2):434-449. PubMed ID: 33479777
[TBL] [Abstract][Full Text] [Related]
10. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
[TBL] [Abstract][Full Text] [Related]
11. Differential Effects of the Interaction Between the Education and APOE ε4 Allele on Amyloid-beta Retention and Memory Performances in Cognitively Normal Older Adults and Alzheimer's Disease Patients.
Kang DW; Wang SM; Na HR; Lee CU; Baek IH; Lim HK
Curr Alzheimer Res; 2020; 17(11):1023-1032. PubMed ID: 33372875
[TBL] [Abstract][Full Text] [Related]
12. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
[TBL] [Abstract][Full Text] [Related]
13. Reference measurement procedure for CSF amyloid beta (Aβ)
Pannee J; Portelius E; Minthon L; Gobom J; Andreasson U; Zetterberg H; Hansson O; Blennow K
J Neurochem; 2016 Nov; 139(4):651-658. PubMed ID: 27579672
[TBL] [Abstract][Full Text] [Related]
14. Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation.
Chatterjee P; Tegg M; Pedrini S; Fagan AM; Xiong C; Singh AK; Taddei K; Gardener S; Masters CL; Schofield PR; Multhaup G; Benzinger TLS; Morris JC; Bateman RJ; Greenberg SM; van Buchem MA; Stoops E; Vanderstichele H; Teunissen CE; Hankey GJ; Wermer MJH; Sohrabi HR; Martins RN; The Dominantly Inherited Alzheimer Network
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805778
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
Palmqvist S; Zetterberg H; Blennow K; Vestberg S; Andreasson U; Brooks DJ; Owenius R; Hägerström D; Wollmer P; Minthon L; Hansson O
JAMA Neurol; 2014 Oct; 71(10):1282-9. PubMed ID: 25155658
[TBL] [Abstract][Full Text] [Related]
16. Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts.
Resnick SM; Bilgel M; Moghekar A; An Y; Cai Q; Wang MC; Thambisetty M; Prince JL; Zhou Y; Soldan A; Wong DF; O'Brien RJ; Ferrucci L; Albert MS
Neurobiol Aging; 2015 Aug; 36(8):2333-9. PubMed ID: 26004017
[TBL] [Abstract][Full Text] [Related]
17. Predictive Accuracy of Blood-Derived Biomarkers for Amyloid-β Brain Deposition Along with the Alzheimer's Disease Continuum: A Systematic Review.
Cianflone A; Coppola L; Mirabelli P; Salvatore M
J Alzheimers Dis; 2021; 84(1):393-407. PubMed ID: 34542072
[TBL] [Abstract][Full Text] [Related]
18. Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome.
Prasher VP; Sajith SG; Mehta P; Zigman WB; Schupf N
Int J Geriatr Psychiatry; 2010 Feb; 25(2):202-7. PubMed ID: 19513990
[TBL] [Abstract][Full Text] [Related]
19. Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden.
Rembach A; Watt AD; Wilson WJ; Villemagne VL; Burnham SC; Ellis KA; Maruff P; Ames D; Rowe CC; Macaulay SL; Bush AI; Martins RN; Masters CL; Doecke JD;
J Alzheimers Dis; 2014; 40(1):95-104. PubMed ID: 24334723
[TBL] [Abstract][Full Text] [Related]
20. Association of cerebrospinal fluid α-synuclein with total and phospho-tau
Vergallo A; Bun RS; Toschi N; Baldacci F; Zetterberg H; Blennow K; Cavedo E; Lamari F; Habert MO; Dubois B; Floris R; Garaci F; Lista S; Hampel H; ;
Alzheimers Dement; 2018 Dec; 14(12):1623-1631. PubMed ID: 30055132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
